Latest News

Isatuximab plus carfilzomib/dexamethasone versus carfilzomib/dexamethasone in patients with relapsed/refractory multiple myeloma: IKEMA Phase III study design




Moreau, P; Dimopoulos, MA; Yong, K; Mikhael, J; Risse, M-L; Asset, G; Martin, T; (2020) Isatuximab plus carfilzomib/dexamethasone versus carfilzomib/dexamethasone in patients with relapsed/refractory multiple myeloma: IKEMA Phase III study design. Future Oncology , 16 (2) pp. 4347-4358. 10.2217/fon-2019-0431 . Green open access

Source link





Related posts

TIVITY HEALTH 72 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors With Losses in Excess of $100,000 of Deadline in Class Action Lawsuit Against Tivity Health, Inc. – TVTY

Newsemia

Medical News Today: Depression during pregnancy: Symptoms, treatment, and more

Newsemia

Endomorph Diet For Weight Loss: Does It Work?

Newsemia

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy